Inhibition of BRAF and BRAF+MEK drives a metastatic switch in melanoma

Por Smalley, Keiran SM, Fedorenko, Inna V
Publicado no Mol Cell Oncol (2015)

The complexity of microenvironment-mediated drug resistance

Por Fedorenko, Inna V., Smalley, Keiran S.M.
Publicado no Genes Cancer (2015)

NRAS mutant melanoma: biological behavior and future strategies for therapeutic management

Por Fedorenko, Inna V., Gibney, Geoffrey T., Smalley, Keiran S. M.
Publicado em 2012

Acquired and intrinsic BRAF inhibitor resistance in BRAF V600E mutant melanoma

Por Fedorenko, Inna V., Paraiso, Kim H. T., Smalley, Keiran S. M.
Publicado em 2011

Amuvatinib has cytotoxic effects against NRAS- but not BRAF-mutant melanoma

Por Fedorenko, Inna V., Fang, Bin, Koomen, John M, Gibney, Geoffrey T., Smalley, Keiran S.M.
Publicado no Melanoma Res (2014)

Managing leptomeningeal melanoma metastases in the era of immune and targeted therapy

Por Smalley, Keiran S.M., Fedorenko, Inna V., Kenchappa, Rajappa, Sahebjam, Solmaz, Forsyth, Peter A.
Publicado no Int J Cancer (2016)

Paradoxical oncogenesis and the long term consequences of BRAF inhibition in melanoma

Por Gibney, Geoffrey T., Messina, Jane L., Fedorenko, Inna V., Sondak, Vernon K., Smalley, Keiran S.M.
Publicado em 2013

BRAF inhibition generates a host/tumor niche that mediates therapeutic escape

Por Fedorenko, Inna V., Wargo, Jennifer A., Flaherty, Keith T., Messina, Jane L., Smalley, Keiran S.M.
Publicado no J Invest Dermatol (2015)

Activity-based protein profiling shows heterogeneous signaling adaptations to BRAF inhibition

Por Sharma, Ritin, Fedorenko, Inna, Spence, Paige T., Sondak, Vernon K., Smalley, Keiran S.M., Koomen, John M.
Publicado no J Proteome Res (2016)

Phosphoproteomic analysis of basal and therapy-induced adaptive signaling networks in BRAF and NRAS mutant melanoma

Por Fedorenko, Inna V., Fang, Bin, Munko, A. Cecelia, Gibney, Geoffrey T., Koomen, John M., Smalley, Keiran S.M.
Publicado no Proteomics (2014)

Senescent fibroblasts in melanoma initiation and progression: an integrated theoretical, experimental, and clinical approach

Por Kim, Eunjung, Rebecca, Vito, Fedorenko, Inna V., Messina, Jane L., Mathew, Rahel, Maria-Engler, Silvya S., Basanta, David, Smalley, Keiran S.M., Anderson, Alexander R.A.
Publicado em 2013

CMET-36. DETECTION, MOLECULAR PROFILING AND CULTURE OF CSF-CTCS IN LEPTOMENINGEAL DISEASE (LMDz) IN MELANOMA

Por Evernden, Brittany, Law, Vincent, Kenchappa, Rajappa, Puskas, John, Ryzhova, Elena, Fedorenko, Inna, Tran, Nam D, Etame, Arnold B, Sahebjam, Solmaz, Magliocco, Anthony, Smalley, Keiran, Forsyth, Peter
Publicado no Neuro Oncol (2017)

XL888 limits vemurafenib-induced proliferative skin events by suppressing paradoxical MAPK activation

Por Phadke, Manali, Gibney, Geoffrey T., Rich, Carolyn J., Fedorenko, Inna V., Chen, Y. Ann, Kudchadkar, Ragini R., Sondak, Vernon K., Weber, Jeffrey, Messina, Jane L., Smalley, Keiran S. M.
Publicado no J Invest Dermatol (2015)

Evaluating Melanoma Drug Response and Therapeutic Escape with Quantitative Proteomics

Por Rebecca, Vito W., Wood, Elizabeth, Fedorenko, Inna V., Paraiso, Kim H. T., Haarberg, H. Eirik, Chen, Yi, Xiang, Yun, Sarnaik, Amod, Gibney, Geoffrey T., Sondak, Vernon K., Koomen, John M., Smalley, Keiran S. M.
Publicado em 2014

A rare case of leptomeningeal carcinomatosis in a patient with uveal melanoma: case report and review of literature

Por Fedorenko, Inna V., Evernden, Brittany, Kenchappa, Rajappa S., Sahebjam, Solmaz, Ryzhova, Elena, Puskas, John, McIntosh, Linda, Caceres, Gisela, Magliocco, Anthony, Etame, Arnold, Harbour, J. William, Smalley, Keiran S.M., Forsyth, Peter A.
Publicado no Melanoma Res (2016)

Inhibition of autophagy enhances the effects of the AKT inhibitor MK-2206 when combined with paclitaxel and carboplatin in BRAF wild-type melanoma

Por Rebecca, Vito W., Massaro, Renato R., Fedorenko, Inna V., Sondak, Vernon K., Anderson, Alexander R.A., Kim, Eunjung, Amavaradi, Ravi K., Maria-Engler, Silvya Stuchi, Messina, Jane L., Gibney, Geoffrey T., Kudchadkar, Ragini R., Smalley, Keiran S. M.
Publicado em 2014

Fibronectin induction abrogates the BRAF inhibitor response of BRAF V600E/PTEN-null melanoma cells

Por Fedorenko, Inna V., Abel, Ethan V., Koomen, John M., Fang, Bin, Wood, Elizabeth R., Chen, Y. Ann, Fisher, Kate J., Iyengar, Sanjana, Dahlman, Kimberly B., Wargo, Jennifer A., Flaherty, Keith T., Sosman, Jeffrey A., Sondak, Vernon K., Messina, Jane L., Gibney, Geoffrey T., Smalley, Keiran S.M.
Publicado no Oncogene (2015)

PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression

Por Paraiso, Kim H.T., Xiang, Yun, Rebecca, Vito W., Abel, Ethan V., Chen, Y. Ann, Munko, A. Cecilia, Wood, Elizabeth, Fedorenko, Inna V., Sondak, Vernon K., Anderson, Alexander R.A., Ribas, Antoni, Palma, Maurizia Dalla, Nathanson, Katherine L., Koomen, John M., Messina, Jane L., Smalley, Keiran S. M.
Publicado em 2011

Ligand independent EphA2 signaling drives the adoption of a targeted therapy-mediated metastatic melanoma phenotype

Por Paraiso, Kim H. T., Thakur, Meghna Das, Fang, Bin, Koomen, John M., Fedorenko, Inna V., John, Jobin K., Tsao, Hensin, Flaherty, Keith T., Sondak, Vernon K., Messina, Jane L., Pasquale, Elena B., Villagra, Alejandro, Rao, Uma N., Kirkwood, John M., Meier, Friedegund, Sloot, Sarah, Gibney, Geoffrey T., Stuart, Darrin, Tawbi, Hussein, Smalley, Keiran S.M.
Publicado no Cancer Discov (2014)